3D Medicines Inc.
Research 3D Medicines Inc. (1244.HK) on Bullrun: market cap HKD 651.69M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1244.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 651.69M
- Financial periodFY2025
- RevenueCNY 356.09M
- Revenue growth-20.1%
- Net income-CNY 177.53M
- Free cash flow-CNY 159.28M
- Gross margin92.1%
Valuation Snapshot
latest market cap is HKD 651.69M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 356.09M | -CNY 177.53M | -CNY 159.28M | 92.1% | -0.72 | CNY 170.24M | CNY 152.78M | CNY 596.73M |
| FY2024 | CNY 445.65M | -CNY 182.66M | -CNY 255.94M | 91.8% | -0.75 | CNY 444.32M | CNY 237.62M | CNY 785.06M |
| FY2023 | CNY 634.95M | -CNY 524.70M | -CNY 150.74M | 92.3% | -2.3 | CNY 666.47M | CNY 282.43M | CNY 936.74M |
| FY2022 | CNY 567.39M | -CNY 1.02B | -CNY 332.76M | 92.6% | -22.52 | CNY 696.74M | CNY 175.70M | CNY 943.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 651.69M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About 3D Medicines Inc.
3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People's Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC, and TMB-H advanced cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is 3D Medicines Inc.'s market cap?
3D Medicines Inc.'s market capitalization is HKD 651.69M.
What does 3D Medicines Inc. do?
3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People's Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors.